NewsNation on MSN10h
AbbVie enters into almost $2B contract with Gubra for obsesity drug
Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.
Here's How to Play AbbVie Stock as it Enters the Obesity Space
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
BioSpace23h
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...
STAT16h
How the race for the next obesity drug is shaping up
While some drugs have fallen off, more have been added: AbbVie recently jumped into the obesity craze by licensing an ...
Wells Fargo Keeps Their Buy Rating on AbbVie (ABBV)
In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...
InnovationRx: Trump’s Tariffs Could Hit Medical Devices, While USAID Cuts Cost Lives
In this week’s InnovationRx newsletter, tariffs could hit medical devices, a gene therapy company that helps blind kids see ...
Medindia3h
Iv m Health Raises Alarm as FDA Deadline Threatens Obesity Treatment Access
In recognition of World Obesity Day,�Ivim Health is proud to advocate on behalf of patients on their health journeys by providing personalized and effective care, guided by medical professionals who ...